ClinicalTrials.gg
CompletedNCT04773002Updated Mar 16, 2022

A Comparison of Volatile Anesthesia and Total Intravenous Anesthesia (TIVA)

An observational study in Rhinoplasty, Ecchymosis and Edema, sponsored by Tokat Gaziosmanpasa University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-03-16.

Sponsored by Tokat Gaziosmanpasa University · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
52
Ages
18 Years to 65 Years
Sex
All
01

Study summary

In this study, investigators wanted to investigate the effect of volatile anesthesia and total intravenous anesthesia (TIVA) on ecchymosis, edema, and intraoperative bleeding in rhinoplasty.

Read the detailed description

Routine monitorization (blood pressure, pulse, oxygen saturation with pulse oximetry and electrocardiogram) will be applied to all patients taken into the operation room.

In Group P (TIVA), induction of anesthesia will be achieved with 2 mg/kg propofol, 0.6 mg/kg rocuronium, and 1 μ / kg fentanyl. Propofol and remifentanil will be used in the continuation of anesthesia.

In Group S (Volatile), anesthesia will be induced with 2 mg / kg propofol, 0.6 mg / kg rocuronium and 1 μ / kg fentanyl. 50% nitrous oxide + 50% oxygen and 2% sevoflurane will be used in the continuation of anesthesia.

All patients will receive 2 ml/kg/hour Ringer's lactate solution during the operation.

02

Conditions studied

  • Rhinoplasty
  • Ecchymosis
  • Edema
  • Hemorrhage
03

In context

Ecchymosis

38 studies on the registry are indexed under Ecchymosis; 6 are open to participants now.

Browse Ecchymosis studies →

Lead sponsor

Tokat Gaziosmanpasa University is the lead sponsor of 170 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Rhinoplasty patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 and 65 years
  • Planned to rhinoplasty
  • An score of 1 or 2

Exclusion criteria

Exclusion Criteria:

  • use
  • Patients with coagulation disorders, •Rejected to participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
52 participants (actual)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Group P

    Total intravenous anesthesia (TIVA)

    Other: Different anesthesia methods

  • Group S

    Volatile anestesia

    Other: Different anesthesia methods

Interventions

  • OtherDifferent anesthesia methods

    Total intravenous anesthesia (TIVA)and volatile anesthesia

06

What researchers measure

Primary outcomes

  1. Edema and ecchymosis in rhinoplasty according to the type of anesthesia.

    It is evaluation developing edema and ecchymosis according to total intravenous anesthesia and volatile anesthesia in rhinoplasty.

    Time frame: one time in six months

07

Study locations

1 site
  • Gaziosmanpasa University
    Tokat, 60200, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04773002
Responsible party
Hakan Tapar (Associate professor, Tokat Gaziosmanpasa University) — Principal investigator
First posted
Feb 26, 2021
Start date
Mar 18, 2021
Primary completion
Aug 21, 2021
Completion
Aug 21, 2021
Last update
Mar 16, 2022

Study contacts

Muzaffer Katar
study chair · Gaziosmanpasa university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion